{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:52:00Z","timestamp":1770976320417,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The effects of teriparatide (TPTD) and alendronate (ALN) on health-related quality of life (HRQOL) were evaluated in osteoporotic patients with high fracture risk using data from the JOINT-05 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>JOINT-05 was a randomized, controlled trial comparing the fracture prevention effects of sequential therapy with TPTD for 72\u00a0weeks followed by ALN for 48\u00a0weeks with those of ALN monotherapy for 120\u00a0weeks. This sub-analysis evaluated the effects of TPTD and ALN on HRQOL using data from baseline to 72\u00a0weeks. HRQOL was assessed at baseline, 4, 12, 24, 48, and 72\u00a0weeks using the EuroQoL-5Dimension (EQ-5D) questionnaire containing five domains (mobility, self-care, usual activities, pain\/discomfort, and anxiety\/depression). Scores were also transformed using utility weights derived from the general Japanese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This sub-analysis included 476 patients in the TPTD group and 492 patients in the ALN group. No significant differences in utility scores were observed between groups at all times. Utility scores improved significantly after 12\u00a0weeks in the TPTD group and after 24\u00a0weeks in the ALN group. Mobility and self-care scores improved significantly in the TPTD group. Significant improvements in usual activity, pain\/discomfort, and anxiety\/depression scores occurred earlier in the TPTD group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there were no significant differences in utility scores between the TPTD and ALN groups, significant improvements in the utility score and 5 domain scores were observed earlier in the TPTD group.<\/jats:p>\n                    <jats:p>When treating osteoporosis patients with a high risk of fracture, the selecting treatment drugs may be decided with primary consideration of its effect on fracture prevention, followed by its effect on improving HRQOL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-025-01621-y","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:47:07Z","timestamp":1753984027000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-5562","authenticated-orcid":false,"given":"Satoshi","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"1621_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/aje\/kwg081","volume":"157","author":"J Magaziner","year":"2003","unstructured":"Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, Wehren L (2003) Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol 157:1023\u20131031. https:\/\/doi.org\/10.1093\/aje\/kwg081","journal-title":"Am J Epidemiol"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00198-004-1622-5","volume":"15","author":"I Hallberg","year":"2004","unstructured":"Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G (2004) Health-related quality of life after osteoporotic fractures. Osteoporos Int 15:834\u2013841","journal-title":"Osteoporos Int"},{"key":"1621_CR4","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1210\/jc.2017-02656","volume":"103","author":"T Tran","year":"2018","unstructured":"Tran T, Bliuc D, Hansen L, Abrahamsen B, van den Bergh J, Eisman JA, van Geel T, Geusens P, Vestergaard P, Nguyen TV, Center JR (2018) Persistence of excess mortality following individual nonhip fractures: a relative survival analysis. J Clin Endocrinol Metab 103:3205\u20133214. https:\/\/doi.org\/10.1210\/jc.2017-02656","journal-title":"J Clin Endocrinol Metab"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s11136-022-03281-1","volume":"32","author":"S Gao","year":"2023","unstructured":"Gao S, Zhao Y (2023) Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Qual Life Res 32:1551\u20131565","journal-title":"Qual Life Res"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376","journal-title":"Lancet"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00198-010-1514-9","volume":"22","author":"JD Adachi","year":"2011","unstructured":"Adachi JD, Lyles KW, Col\u00f3n-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS (2011) Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int 22:2539\u20132549. https:\/\/doi.org\/10.1007\/s00198-010-1514-9","journal-title":"Osteoporos Int"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00198-011-1834-4","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH (2012) Quality of life and health status with zoledronic acid and generic alendronate\u2013a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int 23:2043\u20132051. https:\/\/doi.org\/10.1007\/s00198-011-1834-4","journal-title":"Osteoporos Int"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2474-9-151","volume":"9","author":"AN Lau","year":"2008","unstructured":"Lau AN, Ali SH, Sawka AM, Thabane L, Papaioannou A, Gafni A, Adachi JD (2008) Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet Disord 9:151. https:\/\/doi.org\/10.1186\/1471-2474-9-151","journal-title":"BMC Musculoskelet Disord"},{"key":"1621_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/1471-2474-14-251","volume":"14","author":"\u00d6 Ljunggren","year":"2013","unstructured":"Ljunggren \u00d6, Barrett A, Stoykov I, Langdahl BL, Lems WF, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Karras D, Marin F (2013) Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study. BMC Musculoskelet Disord 14:251. https:\/\/doi.org\/10.1186\/1471-2474-14-251","journal-title":"BMC Musculoskelet Disord"},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00223-016-0143-5","volume":"99","author":"BL Langdahl","year":"2016","unstructured":"Langdahl BL, Ljunggren \u00d6, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E (2016) Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 99:259\u2013271","journal-title":"Calcif Tissue Int"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"030006051987674","DOI":"10.1177\/0300060519876744","volume":"48","author":"T Yang","year":"2020","unstructured":"Yang T, Feng C, Qu Y, Wang Q, Yang Y, Wang B, Sun Z, Bao S (2020) Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study. J Int Med Res 48:0300060519876744","journal-title":"J Int Med Res"},{"key":"1621_CR13","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881905","author":"A Panico","year":"2011","unstructured":"Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G (2011) Teriparatide vs alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover BMD and quality of life. Med Sci Monit. https:\/\/doi.org\/10.12659\/msm.881905","journal-title":"Med Sci Monit"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). J Bone Miner Metab 38:412\u2013417. https:\/\/doi.org\/10.1007\/s00774-019-01074-0","journal-title":"J Bone Miner Metab"},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301\u20132311. https:\/\/doi.org\/10.1007\/s00198-021-05996-2","journal-title":"Osteoporos Int"},{"key":"1621_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","volume":"34","author":"S Mori","year":"2023","unstructured":"Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189\u2013199. https:\/\/doi.org\/10.1007\/s00198-022-06570-0","journal-title":"Osteoporos Int"},{"key":"1621_CR17","unstructured":"EQ-5D: https:\/\/euroqol.org\/publications\/user-guides\/ Accessed 10 Feb 2025"},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5312\/wjo.v13.i6.564","volume":"13","author":"D Patel","year":"2022","unstructured":"Patel D, Liu J, Ebraheim NA (2022) Managements of osteoporotic vertebral compression fractures: a narrative review. World J Orthop 13:564\u2013573","journal-title":"World J Orthop"},{"key":"1621_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14397595.2020.1782592","volume":"31","author":"G Miyamura","year":"2021","unstructured":"Miyamura G, Wakabayashi H, Nagao N, Kato S, Nakagawa T, Naito Y, Sudo A (2021) Prevention of bone loss and improvement of pain-related behavior in hind limb-unloaded mice by administration of teriparatide and bisphosphonate. Mod Rheumatol 31:733\u2013742","journal-title":"Mod Rheumatol"},{"key":"1621_CR20","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.4103\/2152-7806.139653","volume":"5","author":"CM Chen","year":"2014","unstructured":"Chen CM, Lin PY, Chen YC, Jin Y, Huang AP, Lin SH, Hsing MT, Cheng YP, Cheng CY, Lin CT (2014) Effects of teriparatide on lung function and pain relief in women with multiple osteoporotic vertebral compression fractures. Surg Neurol Int 5:S339\u2013S342","journal-title":"Surg Neurol Int"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"e0168691","DOI":"10.1371\/journal.pone.0168691","volume":"11","author":"Z Shi","year":"2016","unstructured":"Shi Z, Zhou H, Pan B, Lu L, Liu J, Kang Y, Yao X, Feng S (2016) Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis. PLoS ONE 11:e0168691","journal-title":"PLoS ONE"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00198-023-06768-w","volume":"34","author":"SE Byun","year":"2023","unstructured":"Byun SE, Lee KJ, Shin WC, Moon NH, Kim CH (2023) The effect of teriparatide on fracture healing after atypical femoral fracture: a systematic review and meta-analysis. Osteoporos Int 34:1323\u20131334","journal-title":"Osteoporos Int"},{"key":"1621_CR23","first-page":"e37478","volume":"15","author":"CS Puvvada","year":"2023","unstructured":"Puvvada CS, Soomro FH, Osman HA, Haridi M, Gonzalez NA, Dayo SM, Fatima U, Sheikh A, Penumetcha SS (2023) Efficacy and safety of teriparatide in improving fracture healing and callus formation: a systematic review. Cureus 15:e37478","journal-title":"Cureus"},{"key":"1621_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00774-014-0574-x","volume":"33","author":"Y Abe","year":"2015","unstructured":"Abe Y, Iba K, Sasaki K, Chiba H, Kanaya K, Kawamata T, Oda K, Amizuka N, Sasaki M (2015) Yamashita T (2015) Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. J Bone Miner Metab 33:125\u2013134","journal-title":"J Bone Miner Metab"},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-010-1495-8","volume":"22","author":"J Iwamoto","year":"2011","unstructured":"Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H (2011) Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int 22:2735\u20132742","journal-title":"Osteoporos Int"}],"updated-by":[{"DOI":"10.1007\/s00774-025-01637-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000}}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01621-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:57:40Z","timestamp":1770973060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01621-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01621-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00774-025-01637-4","URL":"https:\/\/doi.org\/10.1007\/s00774-025-01637-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S Mori has received speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., and Astellas Pharma Inc. S Tanaka has received lecture fees from MSD K.K., Datack Inc., and the Research Institute of Healthcare Data Science. He has received consultation and outsourcing fees from Eli Lilly and Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceutical K.K., and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. H Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma\u00a0S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. T Kuroda declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}